SCHEMBL1421749

SCHEMBL1421749

N#CCCC(c1ccc(C(F)(F)F)cc1)c1c[nH]c2c(C#N)cccc12

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.38
NR3C1 P04150 1/20 0.36
PGR P06401 1/20 0.36
NR3C2 P08235 1/20 0.36
SLC6A4 P31645 4/20 0.34
DYRK1A Q13627 5/20 0.33
GSK3B P49841 2/20 0.33
NFATC1 O95644 1/20 0.33
CYP2D6 P10635 3/20 0.32
SLC6A2 P23975 3/20 0.32
NOS2 P35228 2/20 0.32
KCNH2 Q12809 1/20 0.31
PNP P00491 1/20 0.31
CCNT1 O60563 1/20 0.31
CCNK O75909 1/20 0.31
CCNE1 P24864 1/20 0.31
CDK2 P24941 1/20 0.31
CDK9 P50750 1/20 0.31
CDK12 Q9NYV4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1423259 0.95 CYP19A1 (0.37) CYP19A1NR3C1PGRNR3C2SLC6A4
SCHEMBL1423442 0.88 KDM4E (0.36) CYP19A1SLC6A4CYP2D6SLC6A2KCNH2
SCHEMBL1423731 0.87 AR (0.36) CYP19A1NR3C1PGRNR3C2SLC6A4
SCHEMBL1423619 0.87 DYRK1A (0.40) CYP19A1SLC6A4DYRK1ACYP2D6SLC6A2
SCHEMBL12397673 0.85 MGAM (0.38) CYP19A1NR3C1PGRNR3C2SLC6A4
SCHEMBL2162340 0.85 ALDH1A1 (0.36) CYP19A1SLC6A4CYP2D6SLC6A2KCNH2
SCHEMBL1423093 0.84 HDAC3 (0.44) CYP19A1SLC6A4DYRK1ACYP2D6
SCHEMBL1349693 0.83 CYP19A1 (0.35) CYP19A1SLC6A4CYP2D6SLC6A2KCNH2
SCHEMBL1421817 0.82 AR (0.36) CYP19A1NR3C1PGRNR3C2SLC6A4
SCHEMBL1423209 0.82 DYRK1A (0.40) CYP19A1SLC6A4DYRK1ACYP2D6SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110183928-A1 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-07-28 US disclosed
US-20110183928-A1 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-07-28 US disclosed
EP-2297099-A1 3-CYANOALKYL- AND 3-HYDROXYALKYLINDOLES AND USE THEREOF Bayer Schering Pharma Aktiengesellschaft (DE) 2011-03-23 EP disclosed
WO-2009156091-A1 3-CYANOALKYL- AND 3-HYDROXYALKYLINDOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-12-30 WO disclosed
WO-2009156091-A1 3-CYANOALKYL- AND 3-HYDROXYALKYLINDOLES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183928-A1 3-Cyanoalkyl- and 3-hydroxyalkylindoles and use thereof HTR3C, HTR3A, ADRB3 CYP19A1 3150/4885NR3C1 2099/4885PGR 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.